79
Mostly True
Washington
The website discusses an experimental pill called daraxonrasib that has shown promise in extending the survival of patients with advanced pancreatic cancer. The drug targets a mutated protein in over 90% of cases and has nearly doubled survival time in a study. The FDA is expediting its review.
The claims regarding the drug daraxonrasib and its effects on pancreatic cancer have been corroborated by multiple reliable sources. The evidence indicates that daraxonrasib is a promising treatment for advanced pancreatic cancer, showing significant improvements in survival rates compared to traditional chemotherapy. The FDA's expedited review further supports the potential impact of this drug. Overall, the claims are well-supported by the evidence, leading to a high factual score.
Individual Claims
79
Mostly True
Health
A novel pill helped people with advanced pancreatic cancer live longer.
Multiple sources, including PBS and the Pancreatic Cancer Action Network, report that the novel pill daraxonrasib has shown promise in extending survival for pancreatic cancer patients. The FDA is expediting its review, indicating its potential as a breakthrough treatment. This corroborates the claim that the pill helps people with advanced pancreatic cancer live longer.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
90
Web Consensus Weight
50
Source Quality Score
80
Source Quality Weight
25
Llm Reasoning Score
80
Llm Reasoning Weight
25
Weighted Total
79
Evidence Summary
3 web sources corroborate the claim.
76
Mostly True
Health
The drug daraxonrasib blocks a mutated protein that fuels tumor growth in more than 90% of pancreatic cancer cases.
Evidence from Dana-Farber and MedChemExpress confirms that daraxonrasib is a RAS inhibitor targeting the KRAS gene mutation, which is present in over 90% of pancreatic cancer cases. This supports the claim that the drug blocks a mutated protein fueling tumor growth in these cases.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
85
Web Consensus Weight
50
Source Quality Score
75
Source Quality Weight
25
Llm Reasoning Score
80
Llm Reasoning Weight
25
Weighted Total
76
Evidence Summary
2 web sources corroborate the claim.
79
Mostly True
Health
The daily pills nearly doubled survival time in a study of 500 patients with metastatic pancreatic cancer.
Dana-Farber and 2 Minute Medicine report that daraxonrasib nearly doubled survival time in a Phase 3 trial involving 500 patients with metastatic pancreatic cancer. This evidence strongly supports the claim.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
90
Web Consensus Weight
50
Source Quality Score
80
Source Quality Weight
25
Llm Reasoning Score
80
Llm Reasoning Weight
25
Weighted Total
79
Evidence Summary
2 web sources corroborate the claim.
84
True
Health
Those taking daraxonrasib lived for a median of 13.2 months compared with 6.7 months for chemotherapy recipients.
Dana-Farber and ASCO Post confirm that daraxonrasib increased median survival to 13.2 months compared to 6.7 months for chemotherapy in a Phase 3 trial. This strongly supports the claim.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
95
Web Consensus Weight
50
Source Quality Score
85
Source Quality Weight
25
Llm Reasoning Score
85
Llm Reasoning Weight
25
Weighted Total
84
Evidence Summary
2 web sources corroborate the claim.
79
Mostly True
Health
The FDA plans to expedite review of the drug daraxonrasib.
Multiple sources, including CU Anschutz and Revolution Medicines, confirm that the FDA is expediting the review of daraxonrasib, granting it Breakthrough Therapy Designation. This supports the claim.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
90
Web Consensus Weight
50
Source Quality Score
80
Source Quality Weight
25
Llm Reasoning Score
80
Llm Reasoning Weight
25
Weighted Total
79
Evidence Summary
2 web sources corroborate the claim.
